Oncology Archives - Page 22 of 23

Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis

Authors: C Howlett, S J Snedecor, D J Landsburg, J Svoboda, E A Chong, S J Schuster, S D Nasta, T Feldman, A Rago, K M Walsh, S Weber, A Goy, A...

Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel.

Authors: C J Langer, V Hirsh, I Okamoto, F J Lin, Y Wan, S Whiting, T J Ong, M F Renschler, M F Botteman Published: British Journal of Cancer, 2015 View publication...

Economic impact of 21-gene recurrence score testing on early-stage breast cancer in Ireland

Authors: L Smyth, G Watson, E M Walsh, C M Kelly, M Keane, M J Kennedy, L Grogan, B T Hennessy, S O'Reilly, L E Coate, M O'Connor, C Quinn, K Verleger,...

Penile cancer treatment costs in England

Authors: S T Keeping, M J Tempest, S J Stephens, S M Carroll, V K Sangar Published: BMC Public Health, 2015 View publication Background Penile cancer is a rare malignancy in Western...

Patient-reported outcomes in head and neck and thyroid cancer randomised controlled trials: A systematic review of completeness of reporting and impact on interpretation

Authors: R L Mercieca-Bebber, A Perreca, M King, A Macann, K Whale, S Soldati, M Jacobs, E Efficace Published: European Journal of Cancer, 2016 View publication Aim To determine the completeness of...

Panobinostat plus bortezomib versus lenalidomide in patients with relapsed and/or refractory multiple myeloma: a matching-adjusted indirect treatment comparison of survival outcomes using patient-level data

Authors: I Majer, G van de Wetering, Z Polanyi, A Krishna, E Gray, A Roy Published: Applied Health Economics and Health Policy, 2017 View publication Background In the UK, the standard of...

Post-gemcitabine therapy for patients with advanced pancreatic cancer – a comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.

Authors: A Vogel, F Ciardiello, R A Hubner, J F Blanc, A Carrato, Y Yang, D A Patel, V Ektare, F A de Jong, S Gill Published: Cancer Treatment Reviews, 2016 View...

Risk of skeletal related events among elderly prostate cancer patients by site of metastasis at diagnosis

Authors: A Hussain, A Aly, C Daniel Mullins, Y Qian, J Arellano, E Onukwugha Published: Cancer medicine, 2016 View publication Abstract The purpose of this study was to estimate the risk of...

Budgetary impact of cabazitaxel use after docetaxel treatment for metastatic castration-resistant prostate cancer

Authors: K Flannery, E Drea, L Hudspeth, S Corman, X Gao, M Xue, R Miao Published: Journal of managed care & specialty pharmacy, 2017 View publication Background The headroom method was introduced...

News